Board of Directors Compliance Obligations. The Board of Directors of CHSI shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board of Directors must include independent (i.e., non-executive) members. The Board of Directors shall, at a minimum, be responsible for the following:
a. meeting at least quarterly to review and oversee CHSI’s Compliance Program, including but not limited to the performance of the Corporate Compliance and Privacy Officer and Corporate Compliance Work Group; and
b. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board of Directors summarizing its review and oversight of CHSI’s compliance with Federal health care program requirements and the obligations of this CIA. At minimum, the resolution shall include the following language: “The Board of Directors of the Board of Directors has made a reasonable inquiry into the operations of CHSI’s Compliance Program including the performance of the Corporate Compliance and Privacy Officer and the Corporate Compliance Work Group. Based on its inquiry and review, the Board of Directors has concluded that, to the best of its knowledge, CHSI has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.” Community Health Systems, Inc. Corporate Integrity Agreement If the Board of Directors is unable to provide such a conclusion in the resolution, the Board of Directors shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at CHSI. CHSI shall report to OIG, in writing, any changes in the composition of the Board of Directors, or any actions or changes that would affect the Board of Directors’ ability to perform the duties necessary to meet the obligations in this CIA, within 30 days after such a change.
Board of Directors Compliance Obligations. The Board of Directors (or a committee of the Board) of WCH (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include independent (i.e., non-executive) members. The Board shall, at a minimum, be responsible for the following:
a. meeting at least quarterly to review and oversee WCH’s compliance program, including but not limited to the performance of the Compliance Officer and Compliance Committee;
b. submitting to the OIG a description of the documents and other materials it reviewed, as well as any additional steps taken, such as the engagement of an independent advisor or other third party resources, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period; and
c. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board summarizing its review and oversight of WCH’s compliance with Federal health care program requirements and the obligations of this CIA. At minimum, the resolution shall include the following language: “The Board of Directors has made a reasonable inquiry into the operations of WCH’s Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, WCH has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.” If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at WCH. WCH shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.
Board of Directors Compliance Obligations. The Board shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. The Board shall, at a minimum, be responsible for the following:
a. The Board shall meet at least quarterly to review and oversee GSK’s Compliance Program, including but not limited to the performance of the Compliance Officer and other compliance personnel. The Board shall evaluate the effectiveness of the Compliance Program, including, at a minimum, by receiving updates about the activities of the Compliance Officer and other compliance personnel and updates about adoption and implementation of policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and with applicable Federal health care program and FDA requirements.
b. For each Reporting Period of the CIA, the Board shall adopt a resolution, signed by each individual member of the Board, summarizing its review and oversight of GSK’s compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. At minimum, the resolution shall include the following language: “The Board of Directors has made a reasonable inquiry into the operations of GSK’s Compliance Program as applicable to the CIA (including its Appendices) for the time period [insert time period], including the performance of the Compliance Officer and the compliance personnel who are Covered Persons under this CIA. The Board has concluded that, to the best of its knowledge, GSK has implemented an effective Compliance Program to meet Federal health care program requirements, FDA requirements, and the obligations of the CIA.” If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at GSK. GlaxoSmithKline LLC Corporate Integrity Agreement GSK shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board's ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.
Board of Directors Compliance Obligations. The Board of Directors (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board shall, at a minimum, be responsible for the following:
a. meeting at least quarterly to review and oversee RMC's Compliance Program, including but not limited to the performance of the Compliance Officer and Compliance Committee; and
b. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board summarizing its review and oversight of RMC’s compliance with Federal health care program requirements and the obligations of this CIA. At minimum, the resolution shall include the following language: “The Board of Directors has made a reasonable inquiry into the operations of RMC’s Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, RMC has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.” If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at RMC. RMC shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.
Board of Directors Compliance Obligations. The Board of Directors (Board) shall remain responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board shall, at a minimum, be responsible for the following:
a. meeting at least quarterly to review and oversee LHC's Compliance Program, including but not limited to the performance of the Compliance Officer and Compliance Committee;
b. ensuring that LHC adopts and implements policies, procedures, and practices designed to ensure compliance with the requirements set forth in this CIA and Federal health care program requirements; and
c. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board summarizing its review and oversight of LHC’s compliance with Federal health care program requirements and the obligations of this CIA. At minimum, the resolution shall include the following language: “The Board of Directors has made a reasonable inquiry into the operations of LHC’s Compliance Program including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, LHC has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.” If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at LHC. LHC shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.
Board of Directors Compliance Obligations. The Board of Directors (or a committee of the Board) of Arc (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include independent (i.e., non-executive) members.
a. meeting at least quarterly to review and oversee Arc’s compliance program, including but not limited to the performance of the
Board of Directors Compliance Obligations. The Board of Directors (or a committee of the Board) of NAHC (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include independent (i.e., non-executive) members.
a. meeting at least quarterly to review and oversee NAHC’s compliance program, including but not limited to the performance of the Compliance Officer and Compliance Committee;
b. submitting to OIG a description of the documents and other materials it reviewed, as well as any additional steps taken, such as the engagement of an independent advisor or other third party resources, in its oversight of the compliance program and in support of making the resolution below during each Reporting Period; and
c. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board summarizing its review and oversight of NAHC’s compliance with Federal health care program requirements and the obligations of this CIA.
d. for each Reporting Period of the CIA, the Board shall retain an individual or entity with expertise in compliance with Federal health care program requirements (Compliance Expert) to perform a review of the effectiveness of NAHC’s Compliance Program (Compliance Program Review). The Compliance Expert shall create a work plan for the Compliance Program Review and prepare a written report about the Compliance Program Review. The written report (Compliance Program Review Report) shall include a description of the Compliance Program Review and any recommendations with respect to NAHC’s compliance program. The Board shall review the Compliance Program Review Report as part of its review and oversight of NAHC’s compliance program. A copy of the Compliance Program Review report shall be provided to OIG in each Annual Report submitted by NAHC. In addition, copies of any materials provided to the Board by the Compliance Expert, along with minutes of any meetings between the Compliance Expert and the Board, shall be made available to OIG upon request.
Board of Directors Compliance Obligations. The Board of Directors (or an authorized and designated committee of the Board) of EGS (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include independent (i.e., non-executive) members. The Board (or its authorized and designated Committee) shall, at a minimum, be responsible for the following:
a. meeting at least quarterly to review and oversee EGS's Compliance Program, including but not limited to the performance of the Compliance Officer and Compliance Committee; and
b. for each Reporting Period of the CIA, adopting a resolution, signed by each member of the Board (or its authorized and designated Committee) summarizing its review and oversight of EGS’s compliance with Federal health care program requirements and the obligations of this CIA. At minimum, the resolution shall include the following language: “The Board of Directors has made a reasonable inquiry into the operations of EGS’s Compliance Program, including the performance of the Compliance Officer and the Compliance Committee. Based on its inquiry and review, the Board has concluded that, to the best of its knowledge, EGS has implemented an effective Compliance Program to meet Federal health care program requirements and the obligations of the CIA.” If the Board is unable to provide such a conclusion in the resolution, the Board shall include in the resolution a written explanation of the reasons why it is unable to provide the conclusion and the steps it is taking to implement an effective Compliance Program at EGS. EGS shall report to OIG, in writing, any changes in the composition of the Board, or any actions or changes that would affect the Board’s ability to perform the duties necessary to meet the obligations in this CIA, within 15 days after such a change.
Board of Directors Compliance Obligations. The Board of Directors (or a committee of the Board) of Orbit (Board) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements and the obligations of this CIA. The Board must include independent (i.e., non-executive) members. Committee;
Board of Directors Compliance Obligations. A Committee of the Board of Directors (Committee) shall be responsible for the review and oversight of matters related to compliance with Federal health care program requirements, FDA requirements, and the obligations of this CIA. The Committee shall, at a minimum, be responsible for the following: a. The Committee shall meet at least quarterly to review and oversee Lilly’s Compliance Program, including but not limited to evaluating its effectiveness and receiving updates about the activities of the Chief Compliance Officer and other compliance personnel.
